

Substitute for form 1449B/PTO		ATTORNEY DOCKET NO. 3506.1000-002	APPLICATION NO. 10/757,364
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION FEB 26 2008 LISTING OF REFERENCES February 5, 2008 (Use several sheets if necessary)		FIRST NAMED INVENTOR Steven B. Landau	FILING DATE January 13, 2004
		EXAMINER Yong Soo Chong	CONFIRMATION NO. 3343
			GROUP 1617

U.S. PATENT DOCUMENTS

EXAM -INER -INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AC7	6,194,382	02-27-2001	Crain, <i>et al.</i>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AX5	Wu, Y., <i>et al.</i> , "Effects of Acute and Chronic Administration of MCI-225, a New Selective Noradrenaline Reuptake Inhibitor with 5-HT ₃ Receptor Blocking Action, on Extracellular Noradrenaline Levels in the Hypothalamus of Stressed Rats," <i>Jpn J of Pharmacology</i> , 83, pp. 31-38 (2000).
AY5	Ishigooka, Jr., <i>et al.</i> , "Serotonin-Noradrenaline Reuptake Inhibitors(SNRIs)," <i>Nippon Rinsho</i> , 59, pp. 1523-9, (2001) - Abstract Only.
AZ5	Spiller, R., "Pharmacotherapy: Non-Serotonergic Mechanisms," <i>Gut</i> , 51, Suppl, i87-i90 (2002).

EXAMINER /Yong Chong/	DATE CONSIDERED 03/11/2008
--------------------------	-------------------------------

784516_1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Y.C./